{"id":"paclitaxel-carboplatin-concurrent-radiation","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Neutropenia"},{"rate":"30-50","effect":"Anemia"},{"rate":"20-40","effect":"Thrombocytopenia"},{"rate":"50-70","effect":"Nausea/vomiting"},{"rate":"30-50","effect":"Esophagitis"},{"rate":"10-20","effect":"Pneumonitis"},{"rate":"20-40","effect":"Peripheral neuropathy"},{"rate":"60-80","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1351","moleculeType":"Small molecule","molecularWeight":"371.25"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Paclitaxel stabilizes microtubules and prevents cell division, while carboplatin is a platinum-based alkylating agent that cross-links DNA. When combined with concurrent radiation therapy, the chemotherapy agents enhance radiosensitivity of tumor cells, leading to increased DNA damage and apoptosis. This multimodal approach is particularly effective for locally advanced cancers where combined systemic and local control is needed.","oneSentence":"Paclitaxel and carboplatin chemotherapy combined with concurrent radiation therapy work synergistically to damage cancer cell DNA and inhibit microtubule function, while radiation enhances cytotoxic effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:17.999Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Locally advanced non-small cell lung cancer (NSCLC)"},{"name":"Unresectable stage III NSCLC"}]},"trialDetails":[{"nctId":"NCT04092283","phase":"PHASE3","title":"Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-04-29","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":660},{"nctId":"NCT02905591","phase":"PHASE2","title":"A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Joseph J. Cullen, MD, FACS","startDate":"2018-11-16","conditions":"Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer","enrollment":43},{"nctId":"NCT03044613","phase":"PHASE1","title":"Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2017-07-11","conditions":"Gastric Cancer, Esophageal Cancer, GastroEsophageal Cancer","enrollment":32},{"nctId":"NCT01612351","phase":"PHASE2","title":"Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2012-06","conditions":"Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck","enrollment":40},{"nctId":"NCT06667908","phase":"PHASE2","title":"A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Johnson & Johnson Enterprise Innovation Inc.","startDate":"2024-12-06","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":130},{"nctId":"NCT06984861","phase":"PHASE2","title":"A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-05-13","conditions":"Oropharyngeal Carcinoma","enrollment":74},{"nctId":"NCT05491512","phase":"PHASE2","title":"A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-08-04","conditions":"HPV, Throat Cancer, Oropharyngeal Carcinoma","enrollment":121},{"nctId":"NCT07441681","phase":"PHASE3","title":"Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin","status":"NOT_YET_RECRUITING","sponsor":"NRG Oncology","startDate":"2027-01-06","conditions":"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":454},{"nctId":"NCT03774732","phase":"PHASE3","title":"PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2018-01-24","conditions":"Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4","enrollment":327},{"nctId":"NCT03174275","phase":"PHASE2","title":"Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2017-12-19","conditions":"Carcinoma, Squamous Cell, Oral Cancer, Oropharynx Cancer","enrollment":39},{"nctId":"NCT07423078","phase":"PHASE2","title":"Window of Opportunity in Preserving Laryngeal Function Trial","status":"NOT_YET_RECRUITING","sponsor":"Matthew Spector","startDate":"2026-03-31","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Locally Advanced Laryngeal Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma","enrollment":87},{"nctId":"NCT03141359","phase":"PHASE2","title":"Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2017-05-12","conditions":"Lung Cancer Stage II, Lung Cancer Stage III, Non Small Cell Lung Cancer","enrollment":61},{"nctId":"NCT07385664","phase":"PHASE2","title":"Neoadjuvant Chemoimmunotherapy or Chemoradiotherapy in ESCC","status":"NOT_YET_RECRUITING","sponsor":"Ji Yongling","startDate":"2026-01-28","conditions":"Resectable Esophageal Cancer","enrollment":66},{"nctId":"NCT07162506","phase":"PHASE2","title":"DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-08-01","conditions":"Esophageal Cancer","enrollment":120},{"nctId":"NCT07131319","phase":"PHASE2, PHASE3","title":"SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2025-04-21","conditions":"Non-Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT07371611","phase":"PHASE3","title":"Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Qunxing Li,MD","startDate":"2026-01-01","conditions":"Locally Advanced Oral Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma (OSCC)","enrollment":104},{"nctId":"NCT03829722","phase":"PHASE2","title":"Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2019-09-05","conditions":"Oropharynx Squamous Cell Carcinoma","enrollment":26},{"nctId":"NCT05624996","phase":"PHASE3","title":"Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-07-12","conditions":"Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8","enrollment":474},{"nctId":"NCT03801876","phase":"PHASE3","title":"Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2019-06-26","conditions":"Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8","enrollment":300},{"nctId":"NCT06124118","phase":"PHASE1","title":"Tumor Treating Fields for Locally Advanced NSCLC","status":"RECRUITING","sponsor":"University of Utah","startDate":"2024-04-04","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT02213497","phase":"PHASE1","title":"Dose Escalation of Neoadjuvant Proton Beam Radiotherapy With Concurrent Chemotherapy in Locally Advanced Esophageal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2014-04","conditions":"Esophageal Cancer","enrollment":30},{"nctId":"NCT07317609","phase":"PHASE1","title":"Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-07-15","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":60},{"nctId":"NCT00980954","phase":"PHASE3","title":"Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2009-09","conditions":"Cervical Cancer","enrollment":236},{"nctId":"NCT07306663","phase":"PHASE3","title":"Sintilimab Combined With Chemotherapy Induction Therapy Followed by CCRT vs. CCRT for Esophageal Cancer: A Randomized Controlled Phase Ⅲ Clinical Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2021-06-01","conditions":"Esophageal Cancer","enrollment":242},{"nctId":"NCT04711824","phase":"PHASE1, PHASE2","title":"Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases","status":"RECRUITING","sponsor":"Colette Shen","startDate":"2022-03-09","conditions":"Breast Cancer, Brain Metastases, Adult","enrollment":41},{"nctId":"NCT06866951","phase":"PHASE2, PHASE3","title":"A Clinical Study Comparing Chemotherapy Combined With PD-1 Inhibitor Versus Concurrent Chemoradiotherapy in Cervical Cancer Patients With Positive Lymph Nodes After Surgery: A Multicenter Randomized Controlled Clinical Trial","status":"WITHDRAWN","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2025-03-01","conditions":"Cervical Cancers","enrollment":""},{"nctId":"NCT02621398","phase":"PHASE1","title":"Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2016-08-04","conditions":"Stage II Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer","enrollment":23},{"nctId":"NCT02297217","phase":"PHASE2","title":"Chemoradiotherapy for Advanced Esophageal Cancer","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2019-11-21","conditions":"Esophageal Cancer","enrollment":50},{"nctId":"NCT07271602","phase":"PHASE2","title":"A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-01-30","conditions":"Non Small Cell Lung Cancer, Immunotherapy, Radiotherapy","enrollment":104},{"nctId":"NCT06914011","phase":"PHASE3","title":"Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Asan Medical Center","startDate":"2026-01-06","conditions":"Esophageal Cancer","enrollment":172},{"nctId":"NCT07244965","phase":"PHASE2","title":"Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2025-12-01","conditions":"LOCALLY ADVANCED CERVICAL CANCERS","enrollment":42},{"nctId":"NCT05189730","phase":"PHASE2","title":"Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2021-07-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":80},{"nctId":"NCT04656041","phase":"PHASE2","title":"Folfox+Irinotecan+Chemort In Esophageal Cancer","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2021-06-29","conditions":"Gastroesophageal Junction Adenocarcinoma, Esophagogastric Cancer","enrollment":40},{"nctId":"NCT03916419","phase":"PHASE2","title":"Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-06-20","conditions":"Stage IIB Non-Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer","enrollment":26},{"nctId":"NCT04329065","phase":"PHASE2","title":"Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2022-04-20","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8","enrollment":25},{"nctId":"NCT04615013","phase":"PHASE1","title":"NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-11-23","conditions":"Cervical Esophagus Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8","enrollment":24},{"nctId":"NCT02186847","phase":"PHASE2","title":"Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"NRG Oncology","startDate":"2014-08","conditions":"Adenosquamous Lung Carcinoma, Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma","enrollment":170},{"nctId":"NCT05386888","phase":"PHASE2","title":"A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC","status":"COMPLETED","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","startDate":"2022-09-09","conditions":"NSCLC, Stage III","enrollment":65},{"nctId":"NCT04722523","phase":"PHASE1","title":"A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-01-20","conditions":"Head and Neck Cancer, Head Cancer, Head Cancer Neck","enrollment":40},{"nctId":"NCT01770418","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Proton Collaborative Group","startDate":"2013-03","conditions":"Lung Neoplasms","enrollment":32},{"nctId":"NCT06509568","phase":"PHASE2","title":"Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial）","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-08-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":92},{"nctId":"NCT06420908","phase":"NA","title":"Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)","status":"WITHDRAWN","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2024-05-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT04380636","phase":"PHASE3","title":"Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-06","conditions":"Lung Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":870},{"nctId":"NCT07112833","phase":"PHASE2","title":"A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)","status":"NOT_YET_RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2025-08-10","conditions":"Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma","enrollment":36},{"nctId":"NCT05298423","phase":"PHASE3","title":"Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-05-03","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":611},{"nctId":"NCT07092696","phase":"PHASE2","title":"Induction Immunotherapy Combined With Chemotherapy Followed by Concurrent Chemoradiotherap and Immunotherapy for Cervical Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-12-01","conditions":"Cervical Cancer","enrollment":34},{"nctId":"NCT06290505","phase":"PHASE2","title":"A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study","status":"RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2021-12-08","conditions":"Esophageal Cancer","enrollment":54},{"nctId":"NCT04046575","phase":"PHASE1","title":"Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2019-11-07","conditions":"Esophagus Cancer, Esophageal Cancer, Cancer of the Esophagus","enrollment":12},{"nctId":"NCT06906887","phase":"PHASE2","title":"PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2025-06-17","conditions":"Esophageal Cancer, Oesophageal Cancer, GastroEsophageal Cancer","enrollment":50},{"nctId":"NCT07035808","phase":"PHASE2","title":"a Single Arm, Phase II Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of Iparomlimab and Tuvonralima b and Chemotherapy ± Bevacizumab Induction Therapy Followed by Concurrent Chemoradiotherapy in Patients With Advanced Cervical Cancer .","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-07-01","conditions":"Cervical Cancer Stage IVA, Cervical Cancer Metastatic","enrollment":46},{"nctId":"NCT02730546","phase":"PHASE1, PHASE2","title":"Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2016-06-24","conditions":"Gastric Cardia Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Gastric Cancer AJCC v7","enrollment":31},{"nctId":"NCT04527900","phase":"PHASE2","title":"The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2021-02-23","conditions":"Endometrial Cancer","enrollment":2},{"nctId":"NCT04905316","phase":"PHASE2","title":"A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-05-21","conditions":"Non-small Cell Lung Cancer","enrollment":41},{"nctId":"NCT07015489","phase":"PHASE2","title":"Concurrent Radiotherapy Following Induction Chemoimmunotherapy for Locally Advanced Esophageal Cancer","status":"COMPLETED","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-01-01","conditions":"ESCC","enrollment":44},{"nctId":"NCT04634877","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-01-10","conditions":"Endometrial Neoplasms","enrollment":990},{"nctId":"NCT06110195","phase":"PHASE1","title":"Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2024-01-24","conditions":"Head and Neck Cancer, Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck","enrollment":42},{"nctId":"NCT06990178","phase":"NA","title":"Adaptive Neoadjuvant Therapy for Esophageal Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center","startDate":"2028-03-01","conditions":"Esophageal Carcinoma, Neoadjuvant Therapy","enrollment":43},{"nctId":"NCT03416153","phase":"PHASE2","title":"Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2018-05-21","conditions":"Oropharynx Cancer","enrollment":91},{"nctId":"NCT06861894","phase":"PHASE2","title":"Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC","status":"NOT_YET_RECRUITING","sponsor":"Zhigang Li","startDate":"2025-07","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":164},{"nctId":"NCT03107182","phase":"PHASE2","title":"Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2017-06-27","conditions":"HPV-Related Squamous Cell Carcinoma, HNSCC","enrollment":72},{"nctId":"NCT03064490","phase":"PHASE2","title":"Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)","status":"COMPLETED","sponsor":"Duke University","startDate":"2017-10-17","conditions":"Locally Advanced Esophageal and Gastric Cancers (EGC)","enrollment":35},{"nctId":"NCT04776447","phase":"PHASE2","title":"Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación GECP","startDate":"2021-06-16","conditions":"Lung Diseases, Carcinoma, Non-Small-Cell Lung, Stage IIIA Non-small Cell Lung Cancer","enrollment":38},{"nctId":"NCT06715501","phase":"NA","title":"Efficacy and Safety of Cadonilimab and Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma","status":"ENROLLING_BY_INVITATION","sponsor":"First Affiliated Hospital of Ningbo University","startDate":"2024-12-01","conditions":"Locally Advanced Esophageal Squamous Cell Carcinoma, II-IIIB Stages","enrollment":20},{"nctId":"NCT06870565","phase":"PHASE3","title":"Comparative Study of Adjuvant Therapy for Postoperative Cervical Gastric-type Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2025-03","conditions":"Gastric-type Endocervical Adenocarcinoma, Cervical Cancer","enrollment":238},{"nctId":"NCT05743270","phase":"PHASE2","title":"Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN","status":"WITHDRAWN","sponsor":"Replimune Inc.","startDate":"2024-01-30","conditions":"Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT03937362","phase":"","title":"Pre-Surgery If Needed for Oesophageal Cancer","status":"COMPLETED","sponsor":"Shanghai Chest Hospital","startDate":"2019-08-08","conditions":"Esophageal Cancer","enrollment":200},{"nctId":"NCT04943445","phase":"PHASE2","title":"Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Latin American Cooperative Oncology Group","startDate":"2022-02-22","conditions":"Squamous Cell Carcinoma of Larynx","enrollment":43},{"nctId":"NCT04230408","phase":"PHASE2","title":"Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung Cancers","status":"COMPLETED","sponsor":"Latin American Cooperative Oncology Group","startDate":"2021-03-05","conditions":"Lung Neoplasms","enrollment":48},{"nctId":"NCT06237257","phase":"PHASE2","title":"A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Shengdi Pharmaceutical Co., Ltd","startDate":"2024-03-20","conditions":"Locally Advanced Cervical Cancer","enrollment":56},{"nctId":"NCT01566240","phase":"PHASE3","title":"Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University College, London","startDate":"2012-11-08","conditions":"Cervical Cancer","enrollment":500},{"nctId":"NCT05255653","phase":"PHASE2, PHASE3","title":"Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2021-11-11","conditions":"Endometrial Cancer","enrollment":1615},{"nctId":"NCT05370144","phase":"NA","title":"A Study Involving Neoadjuvant Chemoradiotherapy with Hypofractionated Radiotherapy in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2023-02-08","conditions":"Esophageal Cancer","enrollment":42},{"nctId":"NCT04866017","phase":"PHASE3","title":"A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"BeiGene","startDate":"2021-06-17","conditions":"Non Small Cell Lung Cancer","enrollment":63},{"nctId":"NCT06510660","phase":"PHASE2","title":"Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2024-04-11","conditions":"Esophageal Squamous Cell Carcinoma, Immunotherapy, Biomarkers","enrollment":48},{"nctId":"NCT06599775","phase":"PHASE2","title":"Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-10","conditions":"Resectable Esophageal Squamous Cell Carcinoma","enrollment":42},{"nctId":"NCT02492867","phase":"NA","title":"A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2016-01-14","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":49},{"nctId":"NCT01404156","phase":"PHASE2, PHASE3","title":"Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma","status":"COMPLETED","sponsor":"Dr. Gordon Buduhan","startDate":"2015-09","conditions":"Esophageal Cancer, Adenocarcinoma, Esophageal, Adenocarcinoma, Gastroesophageal Junction","enrollment":29},{"nctId":"NCT06569459","phase":"PHASE2","title":"Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-07-09","conditions":"Esophageal Cancer","enrollment":60},{"nctId":"NCT04435197","phase":"PHASE2","title":"Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2020-08-11","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":143},{"nctId":"NCT06424899","phase":"PHASE2","title":"A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC","status":"RECRUITING","sponsor":"Zeng Jian","startDate":"2024-05-19","conditions":"Non Small Cell Lung Cancer","enrollment":92},{"nctId":"NCT02509286","phase":"PHASE3","title":"Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital Schleswig-Holstein","startDate":"2016-01","conditions":"Esophageal Adenocarcinoma (UICC TNM7), Adenocarcinoma of the Esophagogastric Junction","enrollment":438},{"nctId":"NCT03165994","phase":"PHASE2","title":"APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers","status":"COMPLETED","sponsor":"Apexigen America, Inc.","startDate":"2017-10-06","conditions":"Esophageal Cancer, GastroEsophageal Cancer","enrollment":34},{"nctId":"NCT06366945","phase":"PHASE2","title":"Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-04-20","conditions":"Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, HNSCC","enrollment":85},{"nctId":"NCT06354530","phase":"PHASE2, PHASE3","title":"A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Army Medical Center of PLA","startDate":"2024-03-08","conditions":"Neoadjuvant Therapy, Esophageal Squamous Cell Carcinoma","enrollment":266},{"nctId":"NCT02619448","phase":"EARLY_PHASE1","title":"Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC","status":"RECRUITING","sponsor":"State University of New York - Upstate Medical University","startDate":"2014-12","conditions":"Non-small Cell Lung Cancer","enrollment":12},{"nctId":"NCT06079931","phase":"PHASE2","title":"The Efficacy of Babaodan Capsules in Preventing Radiation Pneumonia","status":"UNKNOWN","sponsor":"Fifth Affiliated Hospital, Sun Yat-Sen University","startDate":"2024-12-05","conditions":"Radiation Pneumonitis","enrollment":30},{"nctId":"NCT02567799","phase":"PHASE1, PHASE2","title":"BIO 300 Non-Small Cell Lung Cancer Study","status":"COMPLETED","sponsor":"Humanetics Corporation","startDate":"2015-11","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":21},{"nctId":"NCT02073968","phase":"PHASE2","title":"PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2013-07","conditions":"Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma","enrollment":35},{"nctId":"NCT03840902","phase":"PHASE2","title":"M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2019-04-16","conditions":"Non-small Cell Lung Cancer","enrollment":153},{"nctId":"NCT02037048","phase":"PHASE2","title":"FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma","status":"UNKNOWN","sponsor":"Case Comprehensive Cancer Center","startDate":"2014-02-10","conditions":"Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Gastric Cardia","enrollment":63},{"nctId":"NCT02916511","phase":"PHASE2","title":"Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Fudan University","startDate":"2016-09-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":70},{"nctId":"NCT03935256","phase":"PHASE2","title":"Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer","status":"UNKNOWN","sponsor":"Loyola University","startDate":"2019-03-05","conditions":"Endometrial Cancer","enrollment":24},{"nctId":"NCT04992780","phase":"PHASE2","title":"Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2022-02-25","conditions":"Non Small Cell Lung Cancer Stage","enrollment":50},{"nctId":"NCT03871153","phase":"PHASE2","title":"Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Greg Durm, MD","startDate":"2019-08-02","conditions":"Non Small Cell Lung Cancer, Stage III Non-small-cell Lung Cancer","enrollment":7},{"nctId":"NCT00411138","phase":"PHASE3","title":"Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer","status":"UNKNOWN","sponsor":"Leiden University","startDate":"2006-11-23","conditions":"Endometrial Cancer","enrollment":670},{"nctId":"NCT05378087","phase":"NA","title":"Comparing the Efficacy of Surgery Staging and Image Staging of Locally Advanced Cervical Cancer","status":"RECRUITING","sponsor":"Chongqing University Cancer Hospital","startDate":"2022-06-27","conditions":"Locally Advanced Cervical Cancer","enrollment":1956},{"nctId":"NCT04764227","phase":"PHASE2","title":"Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2020-05-30","conditions":"Esophagus Cancer, Esophageal Squamous Cell Carcinoma, Chemoradiotherapy","enrollment":70},{"nctId":"NCT00089297","phase":"PHASE2","title":"Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2005-01-06","conditions":"Head and Neck Cancer","enrollment":74},{"nctId":"NCT02850991","phase":"NA","title":"Different Radiation Dose With Concurrent Chemotherapy for Thoracic Esophageal Carcinoma","status":"COMPLETED","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2016-04","conditions":"Esophageal Cancer","enrollment":167},{"nctId":"NCT05872724","phase":"PHASE2","title":"Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)","status":"RECRUITING","sponsor":"Suzhou Municipal Hospital","startDate":"2023-01-16","conditions":"Cervical Cancer","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Paclitaxel+Carboplatin/concurrent radiation","genericName":"Paclitaxel+Carboplatin/concurrent radiation","companyName":"West Japan Thoracic Oncology Group","companyId":"west-japan-thoracic-oncology-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Paclitaxel and carboplatin chemotherapy combined with concurrent radiation therapy work synergistically to damage cancer cell DNA and inhibit microtubule function, while radiation enhances cytotoxic effects. Used for Locally advanced non-small cell lung cancer (NSCLC), Unresectable stage III NSCLC.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}